Blueprint Medicines Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Blueprint Medicines

Access the complete profile.

Blueprint Medicines Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	500 - 1,000Exact Company Size
Primary Industry	5411 Legal Services
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing
Address	45 Sidney St Cambridge, MA 02139

Blueprint Medicines's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Blueprint Medicines's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Blueprint Medicines is classified as operating in the Legal Services industry, NAICS Code 5411.

Blueprint Medicines is a publicly traded company on NMS using the ticker symbol BPMC. Detailed information on company financials and operating reports can be found here: NMS: BPMC

Blueprint Medicines Annual Revenue and Growth Rate

Blueprint Medicines	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$100 - $500 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Blueprint Medicines's revenues are gauged from an analysis of company filings.

Investor Activity

Blueprint Medicines has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date	Investors	Percent Raised	Target Size
November 20, 2014	29	100%	$50 MM
Complete list of funding rounds and total amounts in the Company Report

Trademark Applications

Trademark applications show the products and services that Blueprint Medicines is developing and marketing. Blueprint Medicines doesn't have any recent trademark applications, indicating Blueprint Medicines is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
GAVSETY Pharmaceutical preparations for the treatment of cancer	12/18/2019
GAVSETO Pharmaceutical preparations for the treatment of cancer	12/18/2019
WURKETO Pharmaceutical preparations for the treatment of cancer	11/18/2019

See all trademarks and details in the Full Report.

Market Share of Blueprint Medicines's Largest Competitors

A competitive analysis shows these companies are in the same general field as Blueprint Medicines, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
AUSTIN 316 FIDUCIARY LIMITED	Oceanside, NY	100
CONSILIO	Washington, DC	66
LATHAM & WATKINS	Los Angeles, CA	54
KIRKLAND & ELLIS	Chicago, IL	49
CO STATE FRATERNAL ORDER OF POLICE	Westminster, CO	44
GREENBERG TRAURIG P.A.	Miami, FL	42
PROFESSIONAL LAW ENFORCEMENT A	Rochester, MI	38
CHG COMPANIES	Midvale, UT	35
BAKER & MCKENZIE	Chicago, IL	33

Nearby Competitors

These companies are similar in business line and location to Blueprint Medicines. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
ROPES & GRAY	Boston, MA	100
MINTZ LEVIN COHN FERRIS GLOVSKY & POPEO P.C.	Boston, MA	38
CHOATE HALL & STEWART	Boston, MA	17
WOLF GREENFIELD & SACKS P.C.	Boston, MA	16
GOULSTON & STORRS PC	Boston, MA	15
MANNING GROSS & MASSENBURG	Boston, MA	14

Future Competition: Blueprint Medicines's Fastest Growing Competitors

These companies are in the same general field as Blueprint Medicines and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)